Clinically, PLK1 is established as a prognostic marker and a therapeutic target for the majority of solid, blood, and metastatic cancers, including gastric cancer 19, NSCLC 20, colorectal cancer 48, and prostate cancer 49. Here, PLK1 is linked to Familial prostate cancer.